Research Applications
Age-Related GH Decline (Somatopause)
Ipamorelin research focuses on restoring youthful GH pulsatility in aging adults. Studies demonstrate significant increases in GH pulse amplitude and IGF-1 levels without disrupting circadian GH rhythms. Its clean side effect profile makes it particularly suitable for this application.
Post-Operative Recovery
Phase 2 clinical trials evaluated ipamorelin for post-operative ileus (delayed bowel function recovery). Results showed accelerated return of bowel function and reduced hospital stay following abdominal surgery, with improvements in gastric motility and intestinal transit time.
Body Composition Improvement
Research demonstrates ipamorelin-stimulated GH release promotes lean body mass accretion and visceral fat reduction. Combined with GHRH analogs, studies show improvements in lean mass, fat mass, and body composition parameters in both animal models and human subjects.
Bone Density Enhancement
GH and IGF-1 are critical regulators of bone metabolism. Ipamorelin research shows increased bone mineral density and improved bone formation markers (osteocalcin, P1NP) in preclinical models, suggesting potential applications in osteoporosis prevention and fracture healing.
Sleep Quality and Recovery
GH release is closely linked to slow-wave sleep. Ipamorelin administered before bedtime has been studied for enhancing sleep-related GH pulses, improving sleep quality metrics, and accelerating recovery from physical exertion.
Muscle Injury Recovery
Preclinical studies demonstrate accelerated skeletal muscle regeneration following injury, with increased satellite cell activation, myofiber protein synthesis, and faster functional recovery — mediated through IGF-1-dependent mechanisms.
Mechanism of Action
GHS-R1a Receptor Activation
Ipamorelin binds to the growth hormone secretagogue receptor type 1a (GHS-R1a), a G-protein coupled receptor primarily expressed on somatotroph cells of the anterior pituitary. Receptor activation stimulates the Gq/11 signaling cascade, leading to phospholipase C activation, IP3-mediated calcium release from intracellular stores, and subsequent growth hormone vesicle exocytosis.
Selective GH Release
Ipamorelin's selectivity stems from its specific receptor binding profile — it activates GHS-R1a at the pituitary with high potency but has minimal activity at other receptor subtypes involved in ACTH/cortisol release. Studies demonstrate that even at doses 100-fold above the GH-stimulating dose, ipamorelin does not significantly increase cortisol or ACTH levels — a unique feature among GH secretagogues.
Pulsatile Secretion Pattern
Unlike exogenous growth hormone administration (which produces sustained supraphysiological levels), ipamorelin stimulates pulsatile GH release that preserves the natural rhythm of GH secretion. This pulsatile pattern maintains GH receptor sensitivity and downstream IGF-1 signaling without the receptor desensitization seen with continuous GH exposure.
Synergy with GHRH
Ipamorelin works synergistically with growth hormone releasing hormone (GHRH) and its analogs. While GHRH activates GH synthesis and the cAMP/PKA pathway in somatotrophs, ipamorelin releases stored GH through the calcium/IP3 pathway. Combined administration produces GH release greater than the sum of individual effects.
Somatostatin Functional Antagonism
Ipamorelin partially antagonizes the inhibitory effect of somatostatin on GH release, allowing for GH secretion even during periods of high somatostatin tone. This contributes to more consistent GH stimulation across different physiological states.
Biological Pathways
Gq/11-PLC-IP3/DAG Pathway
GHS-R1a activation couples to Gq/11 proteins, activating phospholipase C (PLC). PLC cleaves PIP2 into IP3 and DAG. IP3 triggers calcium release from the endoplasmic reticulum, while DAG activates protein kinase C (PKC). The resulting calcium surge triggers GH granule exocytosis from somatotroph cells.
GH/IGF-1 Axis
Released GH activates the JAK2/STAT5 signaling pathway in hepatocytes, stimulating hepatic IGF-1 synthesis. Circulating IGF-1 acts through the IGF-1 receptor (a receptor tyrosine kinase) to activate PI3K/Akt and MAPK/ERK pathways in target tissues, promoting protein synthesis, cell proliferation, and metabolic effects.
mTOR/p70S6K Protein Synthesis
GH and IGF-1 signaling converge on the mTOR pathway, activating p70S6K and 4E-BP1 to enhance ribosomal protein synthesis. This is the primary mechanism through which ipamorelin-stimulated GH release promotes muscle protein accretion and tissue repair.
Lipolytic Pathway
GH activates hormone-sensitive lipase (HSL) in adipocytes through a JAK2-mediated mechanism independent of IGF-1, directly stimulating lipolysis. This GH-mediated fat mobilization contributes to improved body composition with favorable fat-to-muscle ratios.
Dosage Information
Calculation Results
Syringe Fill Level (100u syringe)
Protocols
CJC-1295 + Ipamorelin StackIntermediate🏃Sport & Performance3-6 months
The most popular GH secretagogue stack. Synergistic effects for fat loss, muscle gain, recovery, and anti-aging.
Warning: May increase hunger. Water retention possible. Monitor for numbness/tingling.
Comprehensive Longevity StackAdvanced⏳Anti-Aging3-6 months
Multi-peptide anti-aging protocol combining telomerase activation, mitochondrial support, and GH optimization.
Warning: Very advanced protocol. Consider blood work monitoring.
Stability & Storage
Ipamorelin is supplied as a lyophilized white powder. Store lyophilized form at -20°C for long-term stability (18-24 months). At 2-8°C, the powder remains stable for approximately 3-6 months. Protect from light, heat, and moisture.
Reconstitute with bacteriostatic water (0.9% benzyl alcohol preserved) by directing the water stream down the inner wall of the vial. Allow to dissolve gently without shaking. The resulting solution should be clear and colorless. Any cloudiness or particulate matter indicates degradation.
Reconstituted ipamorelin should be stored at 2-8°C and used within 21-28 days. Do not freeze reconstituted solution. The peptide is stable at pH 4-7 but degrades more rapidly at alkaline pH. Avoid mixing with other peptides in the same vial unless compatibility is verified — combination with CJC-1295 or Mod GRF 1-29 in the same vial is commonly practiced but may slightly reduce stability.
Side Effects & Precautions
Injection Site Reactions
Mild redness, swelling, or itching at the injection site is common and typically self-limiting. Rotating injection sites reduces local irritation.
Head Rush and Headache
Transient lightheadedness or mild headache following injection has been reported, possibly related to transient changes in blood glucose or growth hormone effects on cerebral vasculature. Usually resolves within 30-60 minutes.
Water Retention
Mild fluid retention (edema in hands and feet) may occur, particularly during the initial weeks of use. This is a class effect of GH stimulation and typically resolves with continued use as the body adjusts.
Numbness and Tingling
Carpal tunnel-like symptoms (numbness, tingling in hands) can occur due to GH-mediated fluid retention affecting the median nerve. This is dose-dependent and resolves with dose reduction.
Hunger Stimulation
While ipamorelin is significantly less orexigenic than GHRP-6, mild increases in appetite have been reported by some users, likely mediated through residual GHS-R1a activation in hypothalamic feeding centers.
Cortisol and Prolactin (Minimal)
Unlike GHRP-2 and GHRP-6, ipamorelin does not significantly elevate cortisol or prolactin at standard GH-stimulating doses. This selectivity is a key safety advantage over other GH secretagogues.
Research Use Only. This information is for educational and research purposes only. Not intended for medical advice or self-medication.
Regulatory Status
Ipamorelin is not approved by the FDA or any major regulatory authority for clinical use. It has an Investigational New Drug (IND) status and has completed Phase 2 clinical trials for post-operative ileus, but development was not continued to Phase 3.
The peptide is classified as a research chemical and is available from peptide synthesis companies for laboratory research purposes. It is not approved for human therapeutic use in any country.
WADA prohibits ipamorelin under category S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) of the prohibited list, banned both in-competition and out-of-competition. Detection methods using LC-MS/MS can identify ipamorelin and its metabolites in urine for several days after administration.
Research Studies
Ipamorelin, a New Growth-Hormone-Releasing Peptide, Induces Growth Hormone Release Selectively
Raun K, Hansen BS, Johansen NL, et al.
Ipamorelin, a Novel Ghrelin Mimetic, Does Not Release Cortisol or ACTH
Johansen PB, Nowak J, Skjaerbaek C, et al.
Phase 2 Study of Ipamorelin for Post-operative Ileus
Beck DE, Sweeney WB, McCarter MD, et al.
Growth Hormone Secretagogues: History, Mechanism of Action, and Clinical Applications
Ghigo E, Arvat E, Muccioli G, et al.
Selectivity of Ipamorelin as a Growth Hormone Secretagogue
Hansen BS, Raun K, Nielsen KK, et al.
Related Peptides
Sermorelin
Sermorelin Acetate, GRF 1-29 +3 more
CJC-1295
CJC-1295 DAC, CJC-1295 with DAC +3 more
GHRP-2
Growth Hormone Releasing Peptide 2, Pralmorelin +3 more
GHRP-6
Growth Hormone Releasing Peptide 6, Growth Hormone Releasing Hexapeptide +3 more
Hexarelin
Examorelin, HEX +2 more
MK-0677
Ibutamoren, Ibutamoren Mesylate +4 more